Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Tries Out Patent Auction for Biologics

This article was originally published in PharmAsia News

Executive Summary

At a recent patent transfer auction in Shanghai, eight patents were up for grabs, with three of them biomedical intellectual properties. A drug manufacturer under Guangming Group managed to clinch Shanghai Newsummit Biopharma's patented freeze-dry recombinant human growth factor-2 at RMB 18 million. The patented drug received clinical trial approval in July 2005 and is now undergoing a Phase III trial. The product is expected to get a new drug license soon, paving the way for its marketing. Local pharmaceutical companies prefer to invest in a promising drug as higher risks abound during early R&D stages. Experts point out that auctions represent only a means of technology transfer; more critical are market predictions and risk assessments of a product. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts